MedPath

Comparison of efficacy of furosemide alone and albumin-furosemide combination for treatment of edema in nephrotic syndrome childre

Phase 4
Conditions
Health Condition 1: N040- Nephrotic syndrome with minor glomerular abnormality
Registration Number
CTRI/2022/09/045700
Lead Sponsor
Chacha Nehru Bal Chikitsalaya
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Children, between 1-12 years of age, with nephrotic syndrome and refractory edema ( <1% weight loss per day for 5 consecutive days or <5% cumulative weight loss by 5th day of hospitalization after receiving maximum oral dose of furosemide, hydrochlorothiazide or metolazone and IV furosemide bolus in sequence) will be enrolled for the study

Exclusion Criteria

1.Known secondary causes of nephrotic syndrome or with features of glomerulonephritis; like gross hematuria, hypertension, oliguria and deranged kidney function.

2.Children with acute diarrhoea

3.Clinical features of hypovolemia

4.With AKI stage II or III according to KDIGO definition and classification criteria for AKI

5.Children with severe systemic infections; like pneumonia, peritonitis, cellulitis or sepsis

6.Children with respiratory distress

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To determine the mean difference in percentage weight loss at 24 hours in children with nephrotic syndrome and refractory edema receiving furosemide infusion in comparison to those receiving albumin-furosemide combinationTimepoint: 24 hours
Secondary Outcome Measures
NameTimeMethod
1.Mean difference in percentage weight loss between two groups. <br/ ><br>Timepoint: at 48 and 72 hours of therapy
© Copyright 2025. All Rights Reserved by MedPath